Respiratory syncytial virus (RSV) is a leading cause of bronchiolitis and pneumonia worldwide especially in infants, young children, immunocompromised individuals, and the elderly. In the United States alone, the economic burden to treat or prevent severe respiratory disease caused by RSV estimated 6.6 billion dollars in a study conducted with financial reports from 2021. Since its discovery in the late 1950’s, the question of how to elicit a protective immunogenic response against RSV remained unclear, that is, until 2023 when the first FDA approved vaccines became commercially available. These vaccines serve to prevent severe RSV-associated respiratory disease with endpoints involving major economic and quality of life burdens like hospital visits. However, studies have shown that correlates of protection involve antibody responses against two major surface glycoproteins that are required for efficient viral entry: RSV F and RSV G. Currently, all commercially available vaccines and prophylactic monoclonal antibodies use RSV F as their antigenic target. To investigate RSV G as an antigenic target for protective immune responses, commercially unavailable correlates of protection, I develop structure guided RSV G based vaccine designs and determine novel RSV G conformational epitopes recognized by broadly reactive monoclonal antibodies. I begin by discussing our work to address the issue of RSV G’s poor immunogenicity and its association to the apparent immune modulating activity seen in natural infection and vaccination using a nanoparticle vaccine platform where my role was the design, production, and characterization of the vaccine constructs. Following this, I describe a synthetically produced microparticle vaccine design based on layer-by-layer technology where my role was to determine its reactivity with an antibody that relies heavily on correct CX3C folding to recognize the CCD. Finally, I present our structural studies involving five broadly reactive antibodies in complex with the CCD where we characterize three novel conformational epitopes and reveal two non-competing antigenic sites. This work serves as a blueprint for the generation of structure guided mutagenesis, structure guided vaccine design, and antibody therapeutic or prophylactic strategies to protect from and prevent RSV-associated respiratory disease.